Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences

Lee, Christoph I.; Bensink, Mark; Berry, Kristin; Musa, Zahra; Bodnar, Carolyn; Dann, Robert; Jarvik, Jeffrey G.; Lehman, Constance D.; Ramsey, Scott D.

doi:10.1016/j.jacr.2013.09.009

Cited by 10 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Barriers to cost-effective implementation of MRI to reduce unnecessary biopsies prompted by conventional imaging or clinical exam include the relatively low cost associated with image-guided biopsies, which are highly accurate and safe, compared with serial imaging (16) and the high negative predictive value (NPV) (~98%) needed to obviate the biopsy of a suspicious finding based on current American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) guidelines (17). Early studies have demonstrated that the NPV of MRI for this clinical indication ranges from 76% for further evaluation of suspicious mammographic calcifications (18) to 85% in the setting of any suspicious mammographic or clinical finding (19).…”

Section: Introductionmentioning

confidence: 99%

Multiparametric MR Imaging of Breast Cancer

Rahbar

Partridge

2016

Magnetic Resonance Imaging Clinics of North America

View full text Add to dashboard Cite

Synopsis Breast MRI has increased in popularity over the past two decades due to evidence for its high sensitivity for cancer detection. Current clinical MRI approaches rely on the use of a dynamic contrast enhanced (DCE-MRI) acquisition that facilitates morphologic and semi-quantitative kinetic assessments of breast lesions. The use of more functional and quantitative parameters, such as pharmacokinetic features from high temporal resolution DCE-MRI, apparent diffusion coefficient (ADC) and intravoxel incoherent motion (IVIM) on diffusion weighted MRI, and choline concentrations on MR spectroscopy, hold promise to broaden the utility of MRI and improve its specificity. However, due to wide variations in approach among centers for measuring these parameters and the considerable technical challenges, robust multicenter data supporting their routine use is not yet available, limiting current applications of many of these tools to research purposes.

show abstract

Section: Introductionmentioning

confidence: 99%

Multiparametric MR Imaging of Breast Cancer

Rahbar

Partridge

2016

Magnetic Resonance Imaging Clinics of North America

View full text Add to dashboard Cite

show abstract

“…However, the results of several trials using interstitial brachytherapy show no difference in recurrence between strictly selected patients who underwent brachytherapy and those who underwent WBI . After BCS alone, local recurrence rates are known to be increased . We also found that after BCS alone (compared with whole-breast radiotherapy), subsequent treatment after biopsy in the present study is concordant with this finding.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We performed probabilistic, multivariate sensitivity analysis using 10,000 first‐order Monte‐Carlo microsimulation trials. If parameters were not available for a specific input, we assigned a SD of 20% 22 . Three alternative clinical scenarios accounted for common practice variations: 1) cyclophosphamide delivered in an outpatient rather than inpatient setting, 2) filgrastim vials were entered once only, and 3) single‐dose pegfilgrastim replaced filgrastim.…”

Section: Methodsmentioning

confidence: 99%

Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Russell

Chi

Okcu

et al. 2021

Cancer

View full text Add to dashboard Cite

BACKGROUND:The Children's Oncology Group clinical trial for intermediate risk rhabdomyosarcoma randomized participants to a combination of vincristine, dactinomycin, and cyclophosphamide (VAC) alone or VAC alternating with vincristine plus irinotecan (VAC/ VI). Clinical outcomes were similar, but toxicity profiles differed. This study estimates the cost differences between arms from the health care system's perspective. METHODS: A decision-analytic model was used to estimate the incremental cost-effectiveness ratio (ICER) of VAC versus VAC/VI. Protocol-required or recommended medications and laboratory studies were included. Costs were obtained from national databases or supporting literature and inflated to 2019 US dollars. Demographic and outcome data were obtained from the clinical trial and directed chart reviews. Life-years (LY) were estimated from life-expectancy tables and discounted by 3% annually. Probabilistic sensitivity analyses and alternative clinical scenarios identified factors driving costs.

show abstract

Performance Goals for an Adjunct Diagnostic Test to Reduce Unnecessary Biopsies After Screening Mammography: Analysis of Costs, Benefits, and Consequences

Cited by 10 publications

References 14 publications

Multiparametric MR Imaging of Breast Cancer

Multiparametric MR Imaging of Breast Cancer

Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer

Rising drug cost impacts on cost‐effectiveness of 2 chemotherapy regimens for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group

Contact Info

Product

Resources

About